Headline, Upfront, Milestone and Royalty Data for 600+ Agreements

Home Headline, Upfront, Milestone and Royalty Data for 600+ Agreements
Written by Doug Hampton

DUBLIN, June 22, 2023 /PRNewswire/ — The “Global Ophthalmics Partnering 2016-2023: Deal Trends, Players and Financials” report has been added to  ResearchAndMarkets.com’s offering.

Global Ophthalmics Partnering 2016 to 2023 provides the full collection of ophthalmics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering ophthalmics deals.

The report presents financial deal terms values for ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of ophthalmics dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in ophthalmics dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading ophthalmics deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active Ophthalmics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to ophthalmics deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all ophthalmics partnering deals by specific Ophthalmics target announced since 2016. The chapter is organized by specific ophthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all ophthalmics partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in ophthalmics partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of ophthalmics technologies and products.

Report scope

Global Ophthalmics Partnering 2016 to 2023 includes:

  • Trends in ophthalmics dealmaking in the biopharma industry since 2016
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of ophthalmics deal contract documents
  • Comprehensive access to over 600 ophthalmics deal records
  • The leading ophthalmics deals by value since 2016
  • Most active ophthalmics dealmakers since 2016

In Global Ophthalmics Partnering 2016 to 2023, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The report includes deals for the following indications:

  • Age-related macular degeneration
  • Blindness
  • Cataracts
  • Conjunctivitis
  • Diabetic macular edema
  • Dry eye
  • Glaucoma
  • Ocular hypertension
  • Retinal detachment Retinopathy
  • Diabetic retinopathy
  • Uveitis

Companies Mentioned

  • Biohealth Innovation
  • Brigham and Women’s Hospital
  • Alnylam Pharmaceuticals
  • Eastman Chemical Company
  • Apexian Pharmaceuticals
  • Ping An Ventures
  • Eversana
  • Narayana Nethralaya Foundation
  • BLP Management
  • Food and Drug Administration (FDA)
  • Covenant Surgical Partners
  • GHO Capital
  • SBI Capital Markets
  • Nevakar
  • Glenmark Pharmaceuticals
  • Ewopharma
  • KC Pharmaceuticals
  • LV Prasad Eye Institute
  • Cerevast Therapeutics
  • Foundation Fighting Blindness
  • Simulations Plus
  • Laboratoires Thea
  • LambdaVision
  • Bluejay Diagnostics
  • NovaBay Pharmaceuticals
  • Evergaze
  • Columbia Technology Ventures
  • Columbia University
  • Cannabics Pharmaceuticals
  • Aker BioMarine
  • Aura Biosciences
  • AXIM Biotechnologies
  • Mitsubishi Tanabe Pharma
  • Tangible Science
  • ThromboGenics
  • Andrec
  • Evotec
  • Iveric Bio
  • Nordic Prime
  • Bionic Sight
  • Iconic Therapeutics
  • Arctic Vision
  • Cyclica
  • American Academy of Ophthalmology
  • Kali Care
  • Cell Care Therapeutics
  • ArcticDx
  • Wallace H. Coulter Foundation
  • Advanced Dosage Forms
  • AOAExcel
  • Changchun High & New Technology Industries
  • Massachusetts Eye and Ear Infirmary
  • Massachusetts General Hospital

For more information about this report visit https://www.researchandmarkets.com/r/mxypv7

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

Leave a Comment